Claims for Patent: 5,210,085

Summary for Patent: 5,210,085

Title:	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Abstract:	The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularly in the prevention and treatment of AIDS; and the compounds themselves. This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds and related compounds.
Inventor(s):	Liotta; Dennis C. (Stone Mountain, GA), Schinazi; Raymond F. (Decatur, GA), Choi; Woo-Baeg (North Brunswick, NJ)
Assignee:	Emory University (Atlanta, GA)
Application Number:	07/659,760
Patent Claims:	1. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a compound of the formula: ##STR9## 2. The method of claim 1, wherein the pharmaceutically acceptable derivative comprises a monophosphate, diphosphate, or triphosphate ester of 2'-deoxy-5-fluoro-3'-thiacytidine. 3. The method of claim 1, wherein the pharmaceutically acceptable carrier comprises a liposomal suspension. 4. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a .beta.-isomer of a substituted 2'-deoxy-5-fluoro-3'-thiacytidine having the formula: ##STR10## wherein Y is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl and acyl; and R is selected from the group consisting of H, hydroxyl, oxyacyl, monophosphate, diphosphate, and triphosphate. 5. The method of claim 4, wherein the substituted 2'-deoxy-5-fluoro-3'-thiacytidine is selected from the group consisting of the monophosphate, diphosphate, and triphosphate ester of 2'-deoxy-5-fluoro-3'-thiacytidine. 6. The method of claim 4, wherein the pharmaceutically acceptable carrier comprises a liposomal suspension. 7. The method of claim 4, wherein the .beta.-isomer of the substituted 2'-deoxy-5-fluoro-3'-thiacytidine is selected from the group consisting of 4-N-acetyl-2'-deoxy-5-fluoro-3'-thiacytidine; 4-N-acetyl-5'-butyryl-2'-deoxy-5-fluoro-3'-thiacytidine; and 5'-butyryl-2'-deoxy-5-fluoro-3'-thiacytidine. 8. A method for treating a human having an HIV infection comprising administering to the human an effective HIV treatment amount of a compound of the formula: ##STR11## wherein Y is monophosphate, diphosphate, or triphosphate. 9. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a compound of the formula: ##STR12## wherein Y is independently selected from the group consisting of H, alkyl, cycloalkyl, and acyl; and R is selected from the group consisting of H, hydroxyl, oxyacyl, monophosphate, diphosphate, and triphosphate. 10. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a pharmaceutically acceptable salt of a compound of the formula: ##STR13## 11. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of the pharmaceutically acceptable salt of .beta.-isomer of a substituted 2'-deoxy-5-fluoro-3'-thiacytidine having the formula: ##STR14## wherein Y is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl and acyl; and R is selected from the group consisting of H, hydroxy, oxyacyl, monophosphate, diphosphate, and triphosphate. 12. A method for treating a human having an HIV infection comprising administering to the human an effective HIV-treatment amount of a pharmaceutically acceptable salt of a compound of the formula: ##STR15## wherein Y is monophosphate, diphosphate, or triphosphate. 13. A method for treating a human having an HIV infection comprising administering to the human an effective HIV treatment amount of the pharmaceutically acceptable salt of a compound of the formula: ##STR16## wherein Y is independently selected from the group consisting of H, alkyl, cycloalkyl and acyl; and R is selected from the group consisting of H, hydroxyl, oxyacyl, monophosphate, diphosphate, and triphosphate. 14. The method of claim 1, wherein the compound is administered in a pharmaceutically acceptable carrier. 15. The method of claim 4, wherein the compound is administered in a pharmaceutically acceptable carrier. 16. The method of claim 8, wherein the compound is administered in a pharmaceutically acceptable carrier. 17. The method of claim 9, wherein the compound is administered in a pharmaceutically acceptable carrier. 18. The method of claim 10, wherein the compound is administered in a pharmaceutically acceptable carrier. 19. The method of claim 11, wherein the compound is administered in a pharmaceutically acceptable carrier. 20. The method of claim 12, wherein the compound is administered in a pharmaceutically acceptable carrier. 21. The method of claim 13, wherein the compound is administered in a pharmaceutically acceptable carrier.